| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 03/30/2005 | EP1191920B1 Method for permanently shaping keratin fibres, and agents |
| 03/30/2005 | CN1602299A Crystals of bicalutamide and process for their production |
| 03/30/2005 | CN1602197A Use of specific dose of fondaparinux sodium for the treatment of ACS |
| 03/29/2005 | US6872746 Isomeric fused pyrrolocarbazoles and isoindolones |
| 03/29/2005 | US6872707 Prevention, therapy of bacteria infections |
| 03/29/2005 | US6872700 Methods for glucagon suppression |
| 03/29/2005 | US6872390 Local anesthetic methods and kits |
| 03/29/2005 | US6871652 Method for permanently shaping keratin fibers, and agents |
| 03/29/2005 | CA2123717C Compositions containing particles of metallic oxide and hydrophilic organic sunscreen |
| 03/24/2005 | WO2005026192A2 Hpv cd8+ t-cell epitopes |
| 03/24/2005 | WO2005025519A2 Radiolabeled thymidine solid-phase extraction purification method |
| 03/24/2005 | WO2005025518A2 Inhibition of inward sodium currents in cancer |
| 03/24/2005 | WO2005025517A2 Animal model for protease activity and liver damage |
| 03/24/2005 | WO2005025516A2 Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
| 03/24/2005 | WO2005025515A2 Proteasome pathway inhibitors and related methods |
| 03/24/2005 | WO2005025514A2 Compounds that modulate neuronal growth and their uses |
| 03/24/2005 | WO2005025513A2 Guanidinium derivatives for improved cellular transport |
| 03/24/2005 | WO2005025512A2 Cobalamin conjugates for anti-tumor therapy |
| 03/24/2005 | WO2005025511A2 Potassium channel mediated delivery of agents through the blood-brain barrier |
| 03/24/2005 | WO2005025510A2 Cox-2 selective inhibitor with extended duration |
| 03/24/2005 | WO2005025509A2 Methods and materials for treating autoimmune diseases and conditions |
| 03/24/2005 | WO2005025508A2 Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
| 03/24/2005 | WO2005025506A2 Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| 03/24/2005 | WO2005025504A2 Modulators of calcitonin and amylin activity |
| 03/24/2005 | WO2005025503A2 A composition and method of treatment for urogenital conditions |
| 03/24/2005 | WO2005025502A2 A method for treating or inhibiting the effects of injuries or diseases that result in neuronal degeneration |
| 03/24/2005 | WO2005025499A2 Hydrophobic drug compositions containing reconstitution enhancer |
| 03/24/2005 | WO2005025498A2 Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation |
| 03/24/2005 | WO2005025497A2 Hpv cd8+ t-cell epitopes |
| 03/24/2005 | WO2005025496A2 Aliphatic pyrazinoylguanidine sodium channel blockers |
| 03/24/2005 | WO2005025495A2 Methods and compositions for blocking progression of a disease state |
| 03/24/2005 | WO2005025494A2 Vaccine immunotherapy for immune suppressed patients |
| 03/24/2005 | WO2005025493A2 Biological engineering of articular structures containing both cartilage and bone |
| 03/24/2005 | WO2005025492A2 Novel compositions, pharmaceutical compositions, and methods for the treatment and prevention of heart disease |
| 03/24/2005 | WO2005025491A2 Water-soluble polyamioamides as sunscreen agents |
| 03/24/2005 | WO2005025489A2 Therapeutic use of g53135-05(fgf-20) in radiation protection |
| 03/24/2005 | WO2005025487A2 Oligonucleotides targeting prion diseases |
| 03/24/2005 | WO2005011640A3 Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| 03/24/2005 | WO2005011612A3 Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism |
| 03/24/2005 | WO2005011598A3 Leukemia treatment method and composition |
| 03/24/2005 | WO2005011597A3 Compounds and compositions as protein kinase inhibitors |
| 03/24/2005 | WO2005009348A3 Substituted purine derivatives |
| 03/24/2005 | WO2005004797A3 Pharmaceutical dosage forms having overt and covert markings for identification and authentification |
| 03/24/2005 | WO2005004789A3 Method for treating diseases associated with changes of qualitative and/ quantitative composition of blood extracellular dna |
| 03/24/2005 | WO2005000238A3 Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis |
| 03/24/2005 | WO2005000237A3 Granules containing biologically active substances |
| 03/24/2005 | WO2005000215A3 Methods for treating pain |
| 03/24/2005 | WO2005000212A3 Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors |
| 03/24/2005 | WO2004112713A3 Drug polymer complexes |
| 03/24/2005 | WO2004110379A3 A1 adenosine receptor antagonists |
| 03/24/2005 | WO2004110352A3 Compounds having activity in increasing ion transport by mutant-cftr and uses thereof |
| 03/24/2005 | WO2004108090A3 Process for manufacturing oxycodone |
| 03/24/2005 | WO2004108089A3 A micro granulate formulation for oral administration in aqueous suspension |
| 03/24/2005 | WO2004108079A3 Parkin-interacting proteins |
| 03/24/2005 | WO2004105701A3 Compositions and methods for symptomatic relief |
| 03/24/2005 | WO2004105681A3 Cd4+ human papillomavirus (hpv) epitopes |
| 03/24/2005 | WO2004103310A3 Methods and compositions for the treatment of metabolic disorders |
| 03/24/2005 | WO2004103291A3 Extended release compositions of proton pump inhibitor |
| 03/24/2005 | WO2004103282A3 Compounds, compositions and methods |
| 03/24/2005 | WO2004103280A3 Seaweed extract composition for treatment of diabetes and diabetic complications |
| 03/24/2005 | WO2004103266A3 Protein kinase c peptides for use in withdrawal |
| 03/24/2005 | WO2004100889A3 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
| 03/24/2005 | WO2004098509A3 Compositions for inducing immune responses |
| 03/24/2005 | WO2004098494A3 Compounds, compositions, and methods |
| 03/24/2005 | WO2004096135A3 Inhibitors of akt activity |
| 03/24/2005 | WO2004096116A3 Diazabicyclononene derivatives |
| 03/24/2005 | WO2004091546A3 Central nervous system stimulant and opioid antagonist combinations |
| 03/24/2005 | WO2004091535A3 Methods of administering estrogens and progestins |
| 03/24/2005 | WO2004091528B1 Delivery systems of homogeneous thermoreversible alginate films |
| 03/24/2005 | WO2004087075A3 Compositions and methods for treating cancer |
| 03/24/2005 | WO2004087074A3 Process for making substituted pyrazoles |
| 03/24/2005 | WO2004087050A3 Mitotic kinesin inhibitors |
| 03/24/2005 | WO2004084839A3 Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin |
| 03/24/2005 | WO2004084836A3 Methods for treating taxol-induced gut disorder |
| 03/24/2005 | WO2004084815A3 Virulence genes of h. pylori in gastric cancer |
| 03/24/2005 | WO2004082702A8 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy |
| 03/24/2005 | WO2004082609A3 Composition and method for appetite and carving suppression and mood enhancement |
| 03/24/2005 | WO2004078145A3 Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis |
| 03/24/2005 | WO2004075834A3 Stabilized pharmaceutical compositions of safingol and methods of using the same |
| 03/24/2005 | WO2004073641A3 Induced activation in dendritic cells |
| 03/24/2005 | WO2004073619A3 Ccr8 antagonists |
| 03/24/2005 | WO2004071426A3 Compounds for the treatment of viral infection |
| 03/24/2005 | WO2004071387A3 Hsp60 from arthrobacter |
| 03/24/2005 | WO2004069175A3 METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES |
| 03/24/2005 | WO2004069160A3 Chemical compounds |
| 03/24/2005 | WO2004064789A3 Quaternary antimuscarinic compounds for the treatment of bladder diseases |
| 03/24/2005 | WO2004064788A3 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| 03/24/2005 | WO2004064730A3 Compounds, compositions and methods |
| 03/24/2005 | WO2004062588A3 Water-soluble polymeric bone-targeting drug delivery system |
| 03/24/2005 | WO2004060283A3 Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| 03/24/2005 | WO2004056309A3 Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| 03/24/2005 | WO2004047788A8 Functional fragrance precursor |
| 03/24/2005 | WO2004047746A3 Regulation of stearoyl-coa desaturase to treat obesity |
| 03/24/2005 | WO2004041177A3 Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| 03/24/2005 | WO2004012683A9 Novel druggable regions in set domain proteins and methods of using the same |
| 03/24/2005 | US20050065592 System and method of aneurism monitoring and treatment |
| 03/24/2005 | US20050065584 System and method for cooling internal tissue |
| 03/24/2005 | US20050065219 Treatment of demyelinating conditions |
| 03/24/2005 | US20050065209 Citalopram for the treatment of elevated blood pressure |
| 03/24/2005 | US20050065192 Synergistic mixture of methotrexate and integrin antigen or antibody |